Morgan Stanley Initiates Coverage on Omada Health (NASDAQ:OMDA)

Morgan Stanley began coverage on shares of Omada Health (NASDAQ:OMDA) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $25.00 price target on the stock.

Other research analysts also recently issued reports about the stock. Barclays initiated coverage on shares of Omada Health in a research report on Tuesday. They issued an “overweight” rating and a $21.00 price target on the stock. The Goldman Sachs Group began coverage on Omada Health in a research report on Tuesday. They set a “buy” rating and a $29.00 target price on the stock. Canaccord Genuity Group assumed coverage on Omada Health in a research note on Tuesday. They issued a “buy” rating and a $27.00 price objective on the stock. Needham & Company LLC assumed coverage on Omada Health in a research note on Tuesday. They set a “buy” rating and a $23.00 price objective for the company. Finally, JPMorgan Chase & Co. started coverage on shares of Omada Health in a report on Tuesday. They set an “overweight” rating and a $19.00 price target on the stock. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.57.

Omada Health Trading Up 2.9%

NASDAQ OMDA opened at $18.63 on Tuesday. Omada Health has a 52 week low of $14.14 and a 52 week high of $28.40.

About Omada Health

Omada’s mission is to bend the curve. Our hope is that, one day, tomorrow’s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.